Protifarm has succesfully raised funding for its strategic growth plans
Protifarm NV, a Dutch agri-tech leader, has teamed up with a group of investors led by the East Netherlands Development Agency (Oost NL) that focuses its activities on strengthening and stimulating the economy of the provinces of Gelderland and Overijssel, the Netherlands.
As a global pioneer, Protifarm produces functional and sustainable ingredients for the food industry from food-grade farmed insects. The company has a leading position in a fast-growing industry and responds to the urgent need for a healthy lifestyle and to reduce global footprint. Due to population growth and higher prosperity, there is a strong increase in demand for highly nutritious functional ingredients. With the millions of funding that Oost NL and the other investors provide, Protifarm is able to further accelerate its growth and expand its processing capacity. Tom Mohrmann, CEO at Protifarm, said: "Our ingredients contain the quality of animal protein but are far more sustainable than other sources of protein from animals or vegetables."
Oaklins' team in the Netherlands acted as the exclusive fundraising advisor to Protifarm and its shareholders.
Talk to the deal team
Related deals
Tekova Oyj has completed a technical listing on the Nasdaq First North Growth Market Finland
Tekova Oyj has successfully completed a technical listing (IPO) on the Nasdaq First North Growth Market Finland. This transaction marks a significant milestone in the company’s growth strategy, enhancing its visibility and access to capital markets.
Learn moreDuke Capital Limited has completed a fundraising
Duke Capital Limited has completed a successful fundraise, securing US$29.8 million (£23.5 million) through a placing and retail offer on the Alternative Investment Market (AIM). This milestone will further enable Duke Capital to continue its innovative approach to alternative financing solutions for small and medium enterprises (SMEs) across the UK and Europe.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn more